AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|AAPL343.99+4.49 (+1.32%) ▲|ABBV284.80-4.28 (-1.48%) ▼|ABT100.51-1.94 (-1.89%) ▼|ACN240.26+1.14 (+0.48%) ▲|ADBE255.06-1.67 (-0.65%) ▼|AMAT408.94+3.96 (+0.98%) ▲|AMD552.72+17.98 (+3.36%) ▲|AMGN438.34-0.60 (-0.14%) ▼|AMT177.64-5.92 (-3.23%) ▼|AMZN262.37-0.26 (-0.10%) ▼|AVGO337.80+3.43 (+1.03%) ▲|AXP323.61+5.27 (+1.66%) ▲|BA192.28+1.81 (+0.95%) ▲|BAC50.78+0.14 (+0.28%) ▲|BKNG158.38-5.54 (-3.38%) ▼|BLK1,149.60+20.92 (+1.85%) ▲|BMY61.12-0.56 (-0.91%) ▼|BNY145.85+1.60 (+1.11%) ▲|BRK-B538.99-0.83 (-0.15%) ▼|C123.85+1.34 (+1.09%) ▲|CAT740.21+14.97 (+2.06%) ▲|CL93.40-1.14 (-1.21%) ▼|CMCSA22.08-0.28 (-1.25%) ▼|COF206.66+5.10 (+2.53%) ▲|COP145.67-0.28 (-0.19%) ▼|COST998.31+3.70 (+0.37%) ▲|CRM241.78-0.65 (-0.27%) ▼|CSCO107.26+0.55 (+0.52%) ▲|CVS93.45-1.30 (-1.37%) ▼|CVX226.78+1.07 (+0.47%) ▲|DE636.54+4.34 (+0.69%) ▲|DHR233.86+9.62 (+4.29%) ▲|DIS111.83+0.16 (+0.14%) ▲|DUK120.67-0.66 (-0.54%) ▼|EMR163.11+2.65 (+1.65%) ▲|FDX298.23-0.53 (-0.18%) ▼|GD344.71+0.27 (+0.08%) ▲|GE295.88-3.99 (-1.33%) ▼|GEV925.92+35.59 (+4.00%) ▲|GILD153.57-2.94 (-1.88%) ▼|GM76.11-0.98 (-1.27%) ▼|GOOG330.95-5.45 (-1.62%) ▼|GOOGL334.76-5.52 (-1.62%) ▼|GS904.72+19.91 (+2.25%) ▲|HD314.14-0.97 (-0.31%) ▼|HON214.73+1.41 (+0.66%) ▲|IBM251.46+9.54 (+3.94%) ▲|INTC92.96+1.27 (+1.39%) ▲|INTU335.61+0.32 (+0.10%) ▲|ISRG428.12-9.88 (-2.26%) ▼|JNJ257.78-1.58 (-0.61%) ▼|JPM335.19-0.07 (-0.02%) ▼|KO92.68-0.81 (-0.87%) ▼|LIN500.57-1.32 (-0.26%) ▼|LLY1,270.75-12.91 (-1.01%) ▼|LMT551.51+2.80 (+0.51%) ▲|LOW196.56-0.72 (-0.37%) ▼|LRCX260.81-2.64 (-1.00%) ▼|MA622.62+2.20 (+0.35%) ▲|MCD246.25-0.27 (-0.11%) ▼|MDLZ62.74-1.25 (-1.95%) ▼|MDT93.03-1.60 (-1.69%) ▼|META697.52+3.27 (+0.47%) ▲|MMM174.74+3.37 (+1.97%) ▲|MO73.83-0.81 (-1.09%) ▼|MRK149.88+1.58 (+1.07%) ▲|MS187.01+6.61 (+3.66%) ▲|MSFT532.95+1.08 (+0.20%) ▲|MU913.67+17.60 (+1.96%) ▲|NEE78.28-0.58 (-0.74%) ▼|NFLX65.04-3.65 (-5.31%) ▼|NKE37.53-0.35 (-0.92%) ▼|NOW153.12+3.58 (+2.39%) ▲|NVDA221.97+5.50 (+2.54%) ▲|ORCL129.13-2.01 (-1.53%) ▼|PEP134.70+0.68 (+0.51%) ▲|PFE29.85-0.26 (-0.86%) ▼|PG156.84-2.48 (-1.56%) ▼|PLTR201.72+9.12 (+4.74%) ▲|PM197.46-2.44 (-1.22%) ▼|QCOM177.96+2.25 (+1.28%) ▲|RTX191.60-1.74 (-0.90%) ▼|SBUX99.08-0.29 (-0.29%) ▼|SCHW91.64+0.75 (+0.83%) ▲|SO90.39-0.32 (-0.35%) ▼|SPG205.55-1.44 (-0.70%) ▼|T21.91-1.51 (-6.45%) ▼|TMO694.02+6.65 (+0.97%) ▲|TMUS153.75-4.00 (-2.54%) ▼|TSLA386.47+12.76 (+3.41%) ▲|TXN284.65+6.87 (+2.47%) ▲|UBER67.62-1.32 (-1.91%) ▼|UNH417.00-2.26 (-0.54%) ▼|UNP287.87+0.26 (+0.09%) ▲|UPS99.57+1.05 (+1.07%) ▲|USB59.05-0.04 (-0.07%) ▼|V407.85+1.28 (+0.31%) ▲|VZ43.56-0.98 (-2.20%) ▼|WFC82.42+0.22 (+0.27%) ▲|WMT117.80-0.05 (-0.04%) ▼|XOM178.09+0.23 (+0.13%) ▲|
16.8 C
New York
Wednesday, October 21, 2026

Tag: surgery

Prism Pain and Wellness Offering Novel Brain Stimulation to Treat Depression and Optimize Mental Health

ENGLEWOOD, Colo., June 26, 2025 /PRNewswire/ -- The pinnacle of medication-free wellness is now available for those struggling with depression, anxiety and mental fog....

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

Oncorena’s new issue of shares fully subscribed

LUND, Sweden, June 26, 2025 /PRNewswire/ -- Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million...

Oncorena’s new issue of shares fully subscribed

LUND, Sweden, June 26, 2025 /PRNewswire/ -- Today, Oncorena communicates that the new issue of shares was fully subscribed to a sum of 133 million...

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Five University of Colorado Cancer Center Advancements That Changed the Game for Patients

As the CU Cancer Center celebrates its 40th anniversary, here are five ways it helped to change detection and treatment of the disease. AURORA, Colo.,...

Stewart Investors Identifies Six Global Companies Advancing Health Beyond Pharma

Brown & Brown, Cintas Corporation, Haleon, Linde, Raia Drogasil and Veeva Systems are making access to health and hygiene more equitable. EDINBURGH, Scotland, June...

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for ROMVIMZA™ (vimseltinib)

LOUISVILLE, Ky., June 23, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a specialty pharmacy partner by Deciphera Pharmaceuticals, LLC for ROMVIMZA™ (vimseltinib), which has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.1 This indication was approved based on the Phase III MOTION study of ROMVIMZA in patients with tenosynovial giant cell tumor (TGCT).2

Dr. Juan Pablo Umaña Joins the Miller School and UHealth as Chief of Cardiothoracic Surgery

MIAMI, June 23, 2025 /PRNewswire/ -- The Miller School of Medicine and UHealth – University of Miami Health System welcome Juan Pablo Umaña, M.D., an...

Cerapedics Announces FDA Approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator for Lumbar Fusion

ASPIRE pivotal Level-1 PMA IDE study evaluated PearlMatrix vs. local autograft in single-level TLIF procedures:- Demonstrated statistically superior fusion speed;- Achieved over twice as...

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...

U.S. Dermatology Partners Opens New Location in Osage Beach, Missouri

U.S. Dermatology Partners expands access to dermatology care in the Lake of the Ozarks region with the opening of its newest office. OSAGE BEACH, Mo.,...

Insurers Suddenly Discover Compassion—Expect a Fine Print Frenzy

As if the insurance industry needed another reminder that it's universally adored, the titans of health coverage are slinking back from their beloved pastime...

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSurgery